Targeting vascular inflammation through emerging methods and drug carriers

Nong, Jia; Glassman, Patrick M.; Muzykantov, Vladimir R.

doi:10.1016/j.addr.2022.114180

Cited by 29 publications

(16 citation statements)

References 286 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The specificity of sLeX towards activated endothelial cells warrants evaluating whether the specific targeting could also be observed in vivo. E‐selectin expression is commonly upregulated in inflammatory bowel disease in humans and can be modelled by picrylsulfonic acid‐induced colitis in mice (Kawachi et al., 2000 ; Nong et al., 2022 ). Here, Nluc‐labelled EVs were intravenously injected into colitis mice and their levels in tissues and plasma were quantified as previously reported by us (Figure 4a ) (Gupta et al., 2020 ).…”

Section: Resultsmentioning

confidence: 99%

Cell‐specific targeting of extracellular vesicles through engineering the glycocalyx

Zheng

Liang

et al. 2022

J of Extracellular Vesicle

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are promising carriers for the delivery of a variety of chemical and biological drugs. However, their efficacy is limited by the lack of cellular specificity. Available methods to improve the tissue specificity of EVs predominantly rely on surface display of proteins and peptides, largely overlooking the dense glycocalyx that constitutes the outermost layer of EVs. In the present study, we report a reconfigurable glycoengineering strategy that can endogenously display glycans of interest on EV surface. Briefly, EV producer cells are genetically engineered to co‐express a glycosylation domain (GD) inserted into the large extracellular loop of CD63 (a well‐studied EV scaffold protein) and fucosyltransferase VII (FUT7) or IX (FUT9), so that the engineered EVs display the glycan of interest. Through this strategy, we showcase surface display of two types of glycan ligands, sialyl Lewis X (sLeX) and Lewis X, on EVs and achieve high specificity towards activated endothelial cells and dendritic cells, respectively. Moreover, the endothelial cell‐targeting properties of sLeX‐EVs were combined with the intrinsic therapeutic effects of mesenchymal stem cells (MSCs), leading to enhanced attenuation of endothelial damage. In summary, this study presents a reconfigurable glycoengineering strategy to produce EVs with strong cellular specificity and highlights the glycocalyx as an exploitable trait for engineering EVs.

show abstract

Section: Resultsmentioning

confidence: 99%

Cell‐specific targeting of extracellular vesicles through engineering the glycocalyx

Zheng

Liang

et al. 2022

J of Extracellular Vesicle

View full text Add to dashboard Cite

show abstract

“…Apart from the financial constraints, the following scientific concerns should also be considered. 1)Tolerance. [ 306 ] Compared with oncological or other conditions, patients with CVDs have much lower tolerance of side effects. Adverse drug reactions may greatly affect the heart physiological conditions, leading to the dysfunction or even strike of heart. 2)Side effects.…”

Section: Challenges and Future Directions Of Nanomedicines For The Tr...mentioning

confidence: 99%

“…[ 305 ] Nanocarriers such as liposomes, magnetic nanoparticles, ferritin cages, and polymeric nanoparticles have been investigated for vascular delivery of antioxidants. [ 306 ] For instance, Muzykantov and co‐workers reported a PEG–liposome‐based nanomedicine in which a SOD/catalase mimetic drug (EUK‐134) was loaded. [ 307 ] For targeting endothelium, the antibody to PECAM‐1 was further coated on liposome carriers.…”

Section: Nanomedicine For the Treatment Of Ihd And Risk Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Reactive Oxygen Species Scavenging Nanomedicine for the Treatment of Ischemic Heart Disease

Zhang

Dalan

et al. 2022

Advanced Materials

View full text Add to dashboard Cite

Ischemic heart disease (IHD) is the leading cause of disability and mortality worldwide. Reactive oxygen species (ROS) have been shown to play key roles in the progression of diabetes, hypertension, and hypercholesterolemia, which are independent risk factors that lead to atherosclerosis and the development of IHD. Engineered biomaterial‐based nanomedicines are under extensive investigation and exploration, serving as smart and multifunctional nanocarriers for synergistic therapeutic effect. Capitalizing on cell/molecule‐targeting drug delivery, nanomedicines present enhanced specificity and safety with favorable pharmacokinetics and pharmacodynamics. Herein, the roles of ROS in both IHD and its risk factors are discussed, highlighting cardiovascular medications that have antioxidant properties, and summarizing the advantages, properties, and recent achievements of nanomedicines that have ROS scavenging capacity for the treatment of diabetes, hypertension, hypercholesterolemia, atherosclerosis, ischemia/reperfusion, and myocardial infarction. Finally, the current challenges of nanomedicines for ROS‐scavenging treatment of IHD and possible future directions are discussed from a clinical perspective.

show abstract

“…For example, depleting senescent microglia [ 173 , 174 ] helps alleviate inflammation, but it is detrimental to cognition with the elimination of the senescent neuroblasts by natural killer cells during normal brain aging [ 175 , 176 ]. Other reviews proposing theoretical frameworks and potential therapeutic interventions based on inflammation are listed here, including vascular inflammation [ 177 ], immune cell migration [ 178 ], and inflammasomes [ 179 ].…”

Section: Potential Interventionsmentioning

confidence: 99%

Relationships between Inflammation and Age-Related Neurocognitive Changes

Jin

Chan

et al. 2022

IJMS

View full text Add to dashboard Cite

The relationship between inflammation and age-related neurocognitive changes is significant, which may relate to the age-related immune dysfunctions characterized by the senescence of immune cells and elevated inflammatory markers in the peripheral circulation and the central nervous system. In this review, we discuss the potential mechanisms, including the development of vascular inflammation, neuroinflammation, organelle dysfunctions, abnormal cholesterol metabolism, and glymphatic dysfunctions as well as the role that the key molecules play in the immune-cognition interplay. We propose potential therapeutic pharmacological and behavioral strategies for ameliorating age-related neurocognitive changes associated with inflammation. Further research to decipher the multidimensional roles of chronic inflammation in normal and pathological aging processes will help unfold the pathophysiological mechanisms underpinning neurocognitive disorders. The insight gained will lay the path for developing cost-effective preventative measures and the buffering or delaying of age-related neurocognitive decline.

show abstract

Targeting vascular inflammation through emerging methods and drug carriers

Cited by 29 publications

References 286 publications

Cell‐specific targeting of extracellular vesicles through engineering the glycocalyx

Cell‐specific targeting of extracellular vesicles through engineering the glycocalyx

Reactive Oxygen Species Scavenging Nanomedicine for the Treatment of Ischemic Heart Disease

Relationships between Inflammation and Age-Related Neurocognitive Changes

Contact Info

Product

Resources

About